IP Library Granted Patent US 8,304,383
Granted Patent B2
US 8,304,383 · App. 12/024,908 · Granted Nov 6, 2012

Dissolution of arterial plaque

Assignee: AtheroNova Operations, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,304,383
App. No.
12/024,908
Granted
Nov 6, 2012
Kind
B2
Abstract

Embodiments of methods of treating atherosclerosis are described. In some embodiments an emulsifier is provided to achieve levels in the systemic circulation that are effective to solubilize atherosclerotic plaque, resulting in plaque regression. In some embodiments, levels of greater than 50 μM are achieved; in some embodiments levels ranging from about 100 μM to about 600 μM are achieved; in some embodiments, levels ranging from about 100 μM to about 300 μM are achieved. Emulsifiers can include bile salts, saponins, and ionic, nonionic, and zwitterionic detergents, or salts, conjugates, hydrates, solvates, or polymorphs thereof. In some embodiments, a statin can be administered simultaneously or sequentially with an emulsifier.

Claims (17)

1. A method of treating atherosclerosis in a patient in need thereof comprising:

administering a pharmaceutical formulation comprising a bile acid consisting of hyodeoxycholic acid, its pharmaceutically acceptable salt, hydrate, solvate or polymorph in an amount effective to achieve a concentration of the hyodeoxycholic acid in the systemic circulation of greater than 50 μM;

wherein the concentration of the hyodeoxycholic acid in the systemic circulation is sustained for a period of at least two hours;

wherein the concentration of the hyodeoxycholic acid is effective to result in regression of an atherosclerotic plaque.

2. The method of claim 1 , wherein the formulation further comprises at least one of a saponin, a detergent, and mixtures thereof.

3. The method of claim 1 , wherein the sustained levels of the bile acid in the systemic circulation are in a range between about 50 μM and about 600 μM.

4. The method of claim 1 , wherein the sustained levels of the bile acid in the systemic circulation are in a range between about 100 μM and about 300 μM.

5. The method of claim 1 , further comprising using a permeability enhancer.

6. The method of claim 5 , wherein the permeability enhancer comprises at least one of a non-ionic detergent, an ionic detergent, and a zwitterionic detergent.

7. The method of claim 1 , further comprising administering a statin either simultaneously or sequentially with the pharmaceutical formulation.

8. The method of claim 7 , wherein the pharmaceutical formulation further comprises the statin.

9. A method of treating atherosclerosis in a patient in need thereof comprising:

administering a pharmaceutical formulation comprising a bile acid consisting of hyodeoxycholic acid, its acceptable salt, hydrate, solvate, or polymorph in an amount effective to achieve a concentration of the hyodeoxycholic acid in the systemic circulation of greater than 50 μM at five minutes after the onset of administration;

wherein the concentration of the hyodeoxycholic acid in the systemic circulation is sustained above 50 μM for a period of at least two hours; and

wherein the concentration of the hyodeoxycholic acid is effective to result in regression of an atherosclerotic plaque.

10. The method of claim 9 , wherein the sustained levels of the bile acid in the systemic circulation are in a range between about 50 μM and about 600 μM.

11. The method of claim 9 , wherein the sustained levels of the bile acid in the systemic circulation are in a range between about 100 μM and about 300 μM.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2016
From: ATHERONOVA OPERATIONS, INC
To: AHRO IP HOLDINGS LLC
Reel/Frame 040330/0781 →
SECURITY INTEREST Recorded Feb 6, 2015
From: ATHERONOVA INC.; ATHERONOVA OPERATIONS, INC.
To: ACT CAPITAL PARTNERS, LP; AYERLE, ROBERT; CAMPBELL, FRANK J.; ESTATE OF JUDITH W. CAMPBELL; JONATHAN ANDRON ROTH IRA; DELAWARE CHARTER GUARANTEE & TRUST COMPANY; ECKER, AMIR L.; PATRICK K. & ALLISON MK DOYLE FAMILY TRUST; THE ECKER FAMILY PARTNERSHIP; EUROPA INTERNATIONAL, INC.; PAUL, JAY ROBERT; JACOBY, RICHARD A.; THE JMW FUND, LLC; KESZELI, ALEXANDER; KUHN, LARRY A.; LATERAL CAPITAL III, LLC; LIEBROSS, ADAM; LYNCH, JAMES J.; MEYER, CLARENCE J.; MYLI BURGER HOLDINGS, LLC; RUTH R. PECK FAMILY TRUST; RATINER FAMILY 2005 REVOCABLE LIVING TRUST; RICHLAND FUND, LLC; SAN GABRIEL FUND, LLC; SUNTRUST DELAWARE TRUST COMPANY; TILNEY, JOHN J.; VAN NATTA, KYLE; WITTENBRAKER, CAROLYN; W-NET FUND I, LP
Reel/Frame 034911/0516 →
CHANGE OF NAME Recorded Aug 9, 2010
From: Z&Z MEDICAL HOLDINGS, INC.
To: ATHERONOVA OPERATIONS, INC.
Reel/Frame 024809/0610 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2008
From: ZADINI, FILIBERTO P.; ZADINI, GIORGIO C.
To: Z & Z MEDICAL HOLDINGS, INC.
Reel/Frame 021690/0477 →
Continuity (12)
Continuation In Part 11649062 · Jan 3, 2007
Continuation In Part 11384150 · Mar 17, 2006
Continuation In Part 11373943 · Mar 13, 2006
Continuation In Part 12024908
Continuation In Part 11542694 · Oct 4, 2006
Continuation In Part PCTUS2006044619 · Nov 16, 2006
Continuation In Part PCTUS2007001214 · Jan 16, 2007
Provisional Application 60739143 · Nov 22, 2005
Provisional Application 60793379 · Apr 19, 2006
Provisional Application 60930410 · May 15, 2007
Provisional Application 60760471 · Jan 20, 2006
Related Publication 20080187569A1 · Aug 7, 2008